S ickle cell disease (SCD) is among the most prevalent conditions detected on newborn screening 1, 2 and affects nearly 100 000 individuals in the United States. 3, 4 Sickle cell disease comprises distinct hemoglobinopathies with varying phenotypes that portend risk of painful crises and severe infection due to impaired splenic function. Acute chest syndrome (ACS) is 1 of the most common serious complications of SCD, [5] [6] [7] particularly in young children. 6, 8, 9 Acute chest syndrome is diagnosed in 10% of febrile children with SCD presenting to emergency departments 10 and has an incidence of more than 12 episodes per 100 patient-years among individuals with the hemoglobin SS genotype. 9 Acute chest syndrome is a leading cause of hospitalization and death in children 11 and adults 12 with SCD; morbidity and mortality increase with age. 13, 14 First described as "acute chest syndrome" in 1979, 15 ACS
is "an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray." 8(p9) While several different pathophysiologic mechanisms can lead to ACS, including fat embolism and infarction, infectious sources underlie a significant proportion of episodes. 13 Hospitalizations for ACS in children are morbid and resource intensive, averaging 6 days in length, requiring intensive care unit admission in 20% of the cases, involving mechanical ventilation in 9% to 10% of patients, 13, 16 and resulting in readmission within 30 days in 9% of patients. 17 Historically, 1% to 2% of pediatric ACS episodes are fatal. 13 The evidence base for the treatment of ACS in children is lacking. Because establishing a definitive etiology is not always possible, empirical antibiotic therapy is regularly used in ACS. Local, 18 national, 19, 20 and international 21 guidelines recommend this approach, despite the absence of randomized clinical trials evaluating the efficacy of antibiotics for the treatment of ACS. 22 Specifically, the most recent National Heart, Lung, and Blood Institute (NHLBI) guidelines strongly recommend that providers treat ACS "…with an intravenous cephalosporin [and] an oral macrolide antibiotic," despite rating the quality of supporting evidence as low. 20(p1039) Other commonly used ACS treatments, including bronchodilators, 23 blood transfusions, 24 inhaled nitric oxide, 25 and corticosteroids, 26 are also supported by minimal, conflicting, or absent evidence. Although ACS is a common complication of SCD, few centers have sufficient numbers of cases annually to provide meaningful data on patterns of antibiotic treatment for this condition. Therefore, large-scale, multisite data sources are essential. Our objective was to use a large, nationwide database to describe antibiotic administration patterns in children with SCD hospitalized for ACS and determine whether guideline-adherent antibiotic regimens were associated with lower readmission rates.
Methods

Data Source
The Children's Hospital Association's Pediatric Health Information System (PHIS) is a clinical and resource utilization database for US children's hospitals. The PHIS contains discharge and billing data from 49 tertiary pediatric hospitals. Data are maintained by the Children's Hospital Association, participating hospitals, and Truven Health Analytics. Data are deidentified; however, children are assigned unique identifiers to allow for linking across encounters within a hospital. This study of existing, deidentified patient data was not considered human subjects research by the policy and procedures of the Cincinnati Children's Hospital Medical Center Institutional Review Board.
Study Population
Children (aged 0-22 years) with SCD were eligible if they were hospitalized with a discharge diagnosis of ACS between January 1, 2010, and December 31, 2016. We limited our analysis to the 41 of 49 PHIS hospitals that provided complete data throughout the study period. A child was classified as having SCD if he or she had any hospitalization with an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) discharge diagnosis code for SCD (282. 4 10, 16, 17, 28, 30 As with ACS, 22 to our knowledge, no trials exist of antibiotic therapy for communityacquired pneumonia in individuals with SCD. 31 Data were analyzed at the hospitalization level; children could contribute more than 1 hospitalization to the analysis.
Exposures
Using billing records, we collected data on antibiotics administered at any time during the hospitalization. We included oral, intramuscular, and intravenous antibiotics, excluding all other routes (eg, topical) and antimicrobials (eg, antivirals). We also excluded oral penicillin and amoxicillin, assuming that these
Key Points
Question Are guideline-adherent antibiotics associated with reduced readmission rates among children with sickle cell disease hospitalized with acute chest syndrome?
Findings In this cohort study of 14 480 hospitalizations in children with acute chest syndrome, guideline-adherent antibiotic regimens (macrolide with parenteral cephalosporin) were associated with statistically significantly lower 30-day acute chest syndrome and all-cause readmission rates compared with non-guideline-adherent regimens.
Meaning Efforts to increase the dissemination and implementation of sickle cell disease treatment guidelines, in particular as they relate to the antibiotic treatment of children hospitalized with acute chest syndrome, are warranted.
reflected ongoing SCD-related antibiotic prophylaxis and not treatment for ACS. Macrolides included azithromycin, clarithromycin, and erythromycin and were retained regardless of route of administration (oral or intravenous). Cephalosporins of all generations were retained and categorized as parenteral vs oral. While there are no published trials of antibiotic treatment for ACS, 22 several published treatment guidelines exist. [18] [19] [20] [21] 32 We used the most recent NHLBI guideline 20 as the standard against which study data were compared. Specifically, we categorized a child's antibiotic exposure as guideline adherent if it included both a macrolide (oral or intravenous) and a parenteral cephalosporin (ie, macrolide with cephalosporin). Use of only oral cephalosporins was not considered as cephalosporin therapy. Non-guideline-adherent regimens were grouped as (1) cephalosporin without macrolide, (2) macrolide without cephalosporin, or (3) neither macrolide nor cephalosporin. The latter group included children receiving no antibiotics.
Outcomes
Outcomes were assessed during and following the ACS hospitalizations. The primary outcome was hospital readmission, assessed at 7 and 30 days following discharge and categorized as ACS-related (using the same criteria as the primary ACS hospitalization) and all-cause. Thirty-day readmission rates, while controversial, have gained widespread traction as quality metrics, both generally 33, 34 and for SCD. [35] [36] [37] We included 7-day readmissions, consistent with other pediatric readmission studies, [38] [39] [40] [41] in hopes of capturing readmissions most likely to be related to the primary hospitalization (ie, treatment failures). 42 Secondary outcomes for the index hospitalization included the need for intensive care unit admission or invasive mechanical ventilation, death, and length of stay.
Statistical Analysis
Differences in demographic and hospital utilization characteristics between different antibiotic regimens were assessed. We used a χ 2 test for association for categorical variables and the Wilcoxon rank sum test for continuous variables. Multivariable logistic regression was used to assess the association between guideline adherence and readmission. We fit a generalized estimating equation assuming a first-order autoregressive covariance structure to account for potential correlation in outcomes between more than 1 hospitalization within an individual patient. The multivariable logistic regression model included patient attributes (age, sex, insurance, income, presence of ≥1 SCD-related hospitalization in the previous year), hospitalization characteristics (weekend discharge, season, year, hospital volume, ACS diagnosis code, cooccurring asthma diagnosis code), diagnostic variables (chest radiograph performed), nonantibiotic treatments (corticosteroids, bronchodilators, transfusion, mechanical ventilation), and use of cephalosporins and/or macrolides. The model was adjusted for severity of illness, as approximated by the casemix index-a widely used surrogate for illness severity and mortality risk. 43 Case-mix index in the PHIS derives from allpatient-refined diagnosis-related group categories and severity levels. Truven Health Analytics calculates the ratio of the mean charge for patients in a particular all-patient-refined diagnosisrelated group category and severity level combination to the mean charge for all patients in the database. We also fit a hospital-level effect to account for clustering of discharges seen in the same institution and a year effect to account for changes over time. We constructed odds ratios (ORs) and 95% CIs to assess the association between guideline adherence and readmission. Using methods previously described, 44 we performed mixed effect modeling to estimate the proportion of ACS hospitalizations in which each of the 4 antibiotic regimens was used at each of the 41 hospitals, adjusting hospital proportions for patient-level characteristics including age, sex, race, insurance, weekend discharge, season, co-occurring asthma diagnosis code, income, and random hospitalspecific intercepts. We then used logistic regression modeling to assess the association between adjusted antibiotic exposure proportions and hospital ACS volume. The cut-point to determine hospitals with high vs low SCD admissions was determined empirically using piecewise logistic regression models. 45 Hospitals with more than 3444 SCD hospitalizations were considered high-volume centers (n = 16) and those with 3444 SCD hospitalizations or less were considered lowvolume centers (n = 25). All analyses were performed using SAS, version 9.4 (SAS Institute); 2-tailed P values <.05 were considered statistically significant.
Results
Study Sample
Overall, 14 480 hospitalizations involving 7178 children met the inclusion criteria ( 
Antibiotic Use by Hospitalization Attributes
Guideline-adherent antibiotics (macrolide with cephalosporin) were provided in 73.6% of hospitalizations (Table 1) . Cephalosporins but not macrolides were used in 11.6% of hospitalizations and macrolides but not cephalosporins were used in 8.3%. The remaining 6.6% of hospitalizations involved neither a macrolide nor a cephalosporin, including 4.4% with no antibiotics. Children in the younger age groups were most likely to receive recommended antibiotics, with guideline-adherent antibiotic therapy peaking at age 5 to 9 years (79.8%) and decreasing to 64.1% by 19 to 22 years. Hospitalizations associated with a diagnosis code for ACS were more likely than those with a pneumonia diagnosis code to receive recommended antibiotics (79.0% vs 53.8%, P < .001). Guideline-adherent antibiotics were less common in the later years of the study and least common in winter, when ACS prevalence was highest. Hospitalizations during which nonantibiotic treatments (ie, corticosteroids, erythrocyte transfusion, bronchodilators) were used were more likely to also include guideline-adherent antibiotic therapy.
Antibiotic Variation by Hospital
Use of guideline-adherent antibiotics varied widely across the 41 hospitals, ranging from 23.8% to 90.3% (Figure 1 ). Of the 3 least adherent hospitals, 2 had a higher than the mean proportion of children receiving a cephalosporin but no macrolide, and the third had the opposite pattern (higher than the mean proportion of children receiving a macrolide but no cephalosporin). In the latter hospital, the most common antibiotic regimen was a macrolide plus ampicillin (53% of hospitalizations). Use of neither a cephalosporin nor a macrolide ranged from 2% to 19% across hospitals; use of no antibiotics ranged from 0.2% to 12%. There was no association between hospital total ACS volume and the likelihood of using guidelineadherent antibiotics (Figure 2 ).
Outcomes by Antibiotic Regimen
In unadjusted results, readmissions for ACS and all-cause readmissions at 7 and 30 days after hospitalization were lowest in the guideline-adherent antibiotic group ( Table 2) . For all readmission outcomes, the parenteral cephalosporin without macrolide hospitalizations had the second lowest readmission rates. Three of 4 readmission outcomes were highest following hospitalizations involving neither macrolides nor cephalosporins. For the secondary outcomes, guidelineadherent hospitalizations were slightly longer and more likely to involve intensive care unit admission and invasive mechanical ventilation compared with other antibiotic regimens. Only 33 (0.2%) hospitalizations ended in death. In multivariable models, hospitalizations involving both macrolides and cephalosporins were associated with significantly lower readmission rates than those involving neither for 30-day ACS-related (OR, 0.71; 95% CI, 0.50-1.00) and allcause (OR, 0.50; 95% CI, 0.39-0.64) readmissions (Table 3) . When a cephalosporin was used, the addition of a macrolide was associated with a significant decrease in 30-day allcause readmissions (OR, 0.69; 95% CI, 0.56-0.86). When a macrolide was used, the addition of a cephalosporin also reduced 30-day all-cause readmissions, although less so (OR, 0.76; 95% CI, 0.60-0.97).
Discussion
In this large, retrospective, multicenter study of children with SCD hospitalized with ACS, we demonstrated substantial variation in antibiotic delivery. Younger children were more likely to receive NHLBI guideline-adherent 20 antibiotic therapy, as were children receiving nonantibiotic ACS therapies, including erythrocyte transfusion and bronchodilators. Interhospital variation was substantial, with different subgroups of hospitals (1) having consistently high use of guideline-adherent antibiotics; (2) appearing to have a consistent, systematic c The cutpoint to determine hospitals with high vs low SCD admissions was determined empirically using piecewise logistic regression models. 45 Hospitals with more than 3444 SCD hospitalizations were considered high-volume centers (n = 16) and those with 3444 SCD hospitalizations or less were considered low-volume centers (n = 25).
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Association of Antibiotic Treatment in Sickle Cell Disease With Readmission Rates preference for an alternative, non-guideline-adherent approach (eg, ampicillin replacing a cephalosporin); or (3) inconsistently using guideline-adherent antibiotics without a discernible, systematic alternative preference. Children receiving guideline-adherent antibiotics, despite requiring more intensive care unit admissions and mechanical ventilation, had lower 30-day all-cause readmission rates than children treated with non-guideline-adherent regimens. Superior effectiveness of the guideline-adherent antibiotics could explain this difference, but it may be attributable to the slightly longer length of stay observed in children receiving guideline-adherent antibiotics or differences in unmeasured attributes between groups. The relative effect on readmission reduction of the addition of a macrolide for children receiving cephalosporins was somewhat larger than that of the addition of a cephalosporin for children receiving macrolides.
Evidence Base for Guidelines and Metrics for the Antibiotic Treatment of ACS
As with other treatments for ACS in which clinical trial data are minimal, conflicting, or absent, 23-26 to our knowledge, no randomized clinical trial of antibiotic therapy for ACS has been conducted. 22 Lacking research evidence, the 2002 NHLBI guidelines, which were in effect during the early years of the study period, recommended the following: "Intravenous broad-spectrum antibiotics should be given to febrile or severely ill ACS patients since it is difficult to exclude bacterial pneumonia or superinfection of a lung infarct. The MACSS Current NHLBI guidelines, which we deemed the standard and were in effect during the later years of our study, recommend "Treat people with SCD who have ACS with an intravenous cephalosporin, an oral macrolide antibiotic, supplemental oxygen…and close monitoring for bronchospasm, acute anemia, and hypoxemia (strong recommendation, low-quality evidence)." 20(p1039) Finally, SCD experts proposing quality metrics for SCD care 32 similarly recommend that "all children with SCD and ACS should be treated with broad-spectrum antibiotics, including 1 from the macrolide class," and reference the MACSS 13 and a related follow-up study, 46 which demonstrated increased incidence of mycoplasma infection among ACS cases in which an infectious cause was identified. Taken together, these treatment guidelines and quality metrics represent a relatively consistent approach to antibiotic management in children with SCD hospitalized with ACS, but one that is not based on any trial data in this population suggesting superiority of these regimens over narrower spectrum regimens or no regimen.
Antibiotic Variation by Age
We observed a relatively pronounced association between patient age and antibiotic selection, with children 5 to 9 years most likely to receive guideline-adherent antibiotics and adherence decreasing with increasing age. Most of this difference is explained by an increased likelihood, with increasing age, of receiving either a macrolide alone or neither a macrolide nor a cephalosporin. The reason for this age-dependent clinical decision making is unclear. With increasing age, ACS incidence decreases 9 but morbidity and mortality increase. 13, 14 Fever is a less common presenting sign with increasing age, 5, 14 perhaps explaining more aggressive antibiotic administration to younger children. Clinicians caring for younger children may perceive a greater risk of sepsis accompanying the clinical picture of ACS and thus select a more aggressive antibiotic regimen. It is also possible that younger children with ACS are more severely ill, again prompting clinicians to choose a more intensive regimen. Finally, it is possible that infectious causes are more common among younger children and thrombotic and embolic complications are more common among older children. 14 
Antibiotic Variation by Hospital
We also observed substantial interhospital variation in antibiotic use that was not explained by differences in patient volumes. In addition, some variation from guideline-recommended care appeared to be purposeful. One center, for example, routinely used a macrolide and ampicillin, rather than a macrolide and a cephalosporin, in more than half of the children. Another center used a cephalosporin but omitted the macrolide in half of the cases. Interhospital variation may be driven, in part, by local microbiomes and resistance patterns, which we could not measure. This high level of interhospital variation also suggests possible clinician disagreement regarding the ideal antibiotic treatment for children with ACS. This uncertainty creates equipoise for potential future randomized clinical trials comparing the effectiveness of alternative antibiotic regimens. In particular, our data suggest that a narrower antibiotic regimen (eg, macrolide alone) might perform equivalently to currently recommended therapy and should be tested in a randomized clinical trial of low-risk (eg, afebrile) children.
Limitations
As with all studies of administrative data, ours was subject to several limitations, such as possible coding errors, 47 inability to categorize patients by genotype, 48 and a lack of detailed clinical information (eg, chest radiograph reports). This lack of clinical information limited our ability to stratify patients precisely by level of illness, leaving open the possibility that clinicians chose different antibiotics depending on the perceived severity of the patient's illness. Furthermore, because antibiotic regimens were selected as part of normal hospital care (ie, not randomized), other unmeasured confounders may have made the treatment groups different in ways other than differential exposure to antibiotics. We used modeling to account for variables captured in the PHIS that could be expected to confound these associations, but unmeasured confounders likely remain, such as the presence of other chronic, comorbid conditions (eg, asthma), outpatient treatments (eg, hydroxyurea), or access to comprehensive, timely follow-up after hospital discharge. Consistent with previous studies, our definition of ACS included hospitalizations with diagnosis codes for ACS or pneumonia. While there is substantial clinical overlap between these conditions, and therefore presumed coding overlap, they are distinct clinical phenomena. 7 Future studies with richer clinical data might be better able to discriminate between ACS and pneumonia. Finally, we used the 2014 guideline recommendations as our standard, but prescribing during the early years of the study occurred when the 2002 guidelines were in effect. Use of the 2014 guidelines could have caused us to underestimate guideline adherence in study years before 2014. However, this limitation would not affect our conclusion regarding the effectiveness of guidelineadherent therapy.
Conclusions
Children with SCD who develop ACS are at risk of serious morbidity and death. Timely, effective treatment for such children is essential to reduce their risk of harm, including the readmissions that more than 1 in 8 children hospitalized with ACS experience. Current approaches to antibiotic treatment in children with ACS vary widely, so more robust dissemination and implementation of existing treatment guidelines may reduce readmissions in this high-risk population. Furthermore, randomized clinical trials of antibiotics for the treatment of ACS in children, perhaps comparing guideline-recommended and narrower (eg, macrolide-only) regimens for lower risk children, are needed to strengthen the evidence base underpinning current recommendations.
